What is BroadPharm?
BroadPharm is a prominent biotechnology firm dedicated to the manufacturing and worldwide distribution of high-purity chemical compounds essential for drug development. Their comprehensive product catalog features over 8,000 PEG linkers and 2,000 Click Chemistry reagents, alongside specialized components for Antibody-Drug Conjugates (ADCs) and drug delivery lipids. These offerings are crucial for pharmaceutical and biotech entities aiming to accelerate their research and development pipelines. Beyond its product range, BroadPharm provides custom synthesis services and bioconjugation kits, reinforcing its role as a key enabler in advanced therapeutic research.
How much funding has BroadPharm raised?
BroadPharm has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in BroadPharm
PPP
Public-Private Partnership
What's next for BroadPharm?
The substantial capital infusion, characterized as a large-scale late-stage funding event, positions BroadPharm for significant growth and strategic advancements. This backing is expected to fuel further innovation in their product development, potentially expanding their market reach and enhancing their custom service capabilities. The company's focus on high-purity reagents and specialized linkers suggests a strategic emphasis on supporting cutting-edge therapeutic modalities like ADCs and novel drug delivery systems, indicating a forward-looking approach to addressing unmet needs in the pharmaceutical industry.
See full BroadPharm company page
